The AIM-HI Accelerator Fund is proud to support our Portfolio Company, SciTech Development, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 11-12, 2021, co-hosted…
The AIM-HI Accelerator Fund sincerely thanks Microsoft for being a generous sponsor and supporting our inaugural Women’s Venture Competition program to provide various opportunities to women-led oncology start-ups! Only 2% of all venture money go to women-led early stage companies.…
Tvardi Therapeutics, an AIM-HI Accelerator Fund portfolio company, has won recognition as one of the ten “Most Promising” companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is…
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare…
Congratulations to the inaugural AIM-HI Women’s Venture Competition finalists selected by the Judging Committee, Stacy Blain of Concarlo Holdings and Manijeh Goldberg of Privo Technologies. Not only are they advancing science, but they are also paving the way for more…
It’s 2020, and still only 2.2% of all venture capital dollars go to companies led by women entrepreneurs in life sciences. Let’s change that! Join us on Thursday, September 24, at the AIM-HI Women’s Venture Competition Award Ceremony as we celebrate…
Serial entrepreneur Ken Malone, Ph.D., and his team of scientists and business executives are at the forefront of developing cutting-edge biohealth companies. Malone is the Chairman of the Board of Directors of Rasio Therapeutics, a start-up which is bringing innovative…
The 8 semi-finalists are just announced in the AIM-HI Accelerator Fund's inaugural Women’s Venture Competition! These innovative oncology startups are selected from an exceptional pool of high quality women entrepreneur applications, by a Selection Committee comprised of world-class key opinion…
Imran Alibhai, Ph.D., is the CEO of Tvardi Therapeutics, a biopharmaceutical company developing breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. The National Foundation for Cancer Research and AIM-HI Accelerator Fund have been early financial supporters of…
Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its…
